<DOC>
	<DOCNO>NCT01140139</DOCNO>
	<brief_summary>In study , investigator evaluate therapeutic HIV-1 DNA vaccine administer novel topical application method 12 chronically HIV-infected cART treat patient . The HIV DNA plasmid use study encode envelope gp160 HIV-1 subtypes A , B C , rev B , Gag A B reverse transcriptase ( RT ) B . The patient randomly assign three group ; group 1 ( n=4 ) immunize six time 0.4 mg HIV DNA plasmid topically , group 2 ( n=4 ) immunize six time 0.4 mg HIV DNA plasmid topically treat 500 mg hydroxyurea daily visit 10 , group 3 ( n=4 ) four patient receive placebo . The immunization perform three cycle 7 week cART follow four week therapy interruption . After last cycle cART patient maintain definitive treatment interruption CD4+ T cell count drop 350/ mm3 two time point . Cellular humoral immune response , viral load CD4+ T cell count analyse throughout study .</brief_summary>
	<brief_title>Dermal HIV-1 Immunization During Anti-retroviral Therapy Followed Repeated Treatment Interruptions</brief_title>
	<detailed_description />
	<mesh_term>Hydroxyurea</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Aged 18 60 year 2 . Female , document infertile menopause since least 1 year , male , willing father child duration study . 3 . HIV infection detect two serological and/or HIV plasma RNA test 4 . On HAART least 6 month le 50 copies/ml plasma HIV1 RNA two determination 3 month 5 . Current CD4 count 400 6 . CD4 count nadir &gt; 200 7 . Viral isolate pre ART available preferable mandatory 8 . Willing consider stop HAART repeatedly . 9 . Willing conform low alcohol intake ( maximum one glass per day ) 10 . Able tolerate didanosine hydroxyurea 11 . Willing change HAART exclude NNRTI stavudine 12 . Able give inform consent 13 . Availability followup plan duration study 1 . Patients ongoing infection ( ) HIV . 2 . Prior current pancreatitis history alcohol abuse . 3 . Ongoing neuropathy history grade 1 neuropathy . 4 . History mutation one class antiretroviral drug switch drug due failure . 5 . Sun solarium exposure immunize site one month trial . 6 . Cortisone treatment , systemic local immunizing site , one month trial . 7 . Patients sign autoimmune diseases 8 . Patients creatinine &gt; 2mg/dl , Hb &lt; 12g/dl , leukocytes &lt; 3,000ul , platelet &lt; 150,000/ul LFT &gt; 5x upper limit normal 9 . Patients immune modulating investigational drug 10 . Anamnestic allergy kanamycin , plasmid gene product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2006</verification_date>
</DOC>